10.1 Non-Sterile Compounding: USP <795> & the Massachusetts Overlay

Non-sterile pharmaceutical compounding plays a critical role in personalized patient care, allowing pharmacists to prepare customized dosage forms, strengths, and flavorings when commercially manufactured drug products are unavailable or clinically inappropriate. In the United States, non-sterile compounding is governed by United States Pharmacopeia (USP) General Chapter <795> (Pharmaceutical Compounding — Nonsterile Preparations), which is enforced by the U.S. Food and Drug Administration (FDA) under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and state boards of pharmacy. In Massachusetts, the Board of Registration in Pharmacy enforces USP <795> alongside dedicated state regulations under 247 CMR 18.00 (Non-Sterile Compounding).

Pharmacy jurisprudence exams such as the MPJE heavily test the distinction between compounding under Section 503A (patient-specific prescriptions prepared by a licensed pharmacy) and manufacturing under Section 503B (outsourcing facilities compounding bulk sterile/non-sterile preparations without individual patient prescriptions). Candidates must master compounding complexity classifications, strict Beyond-Use Date (BUD) calculation parameters, documentation requirements, and Massachusetts-specific licensing mandates.

---

Categorization of Non-Sterile Compounding Complexity

USP <795> establishes three distinct levels of non-sterile compounding complexity based on the difficulty of preparation, dosage form stability, ingredient risk, and special facility or process requirements:

Exam Trap: Simple reconstitutions of commercial oral powders (e.g., reconstitution of amoxicillin powder for suspension with purified water) do not require a Master Formulation Record under USP <795> unless customized alterations or non-manufacturer ingredients are introduced.

---

Beyond-Use Date (BUD) Calculation Rules

A critical distinction on the MPJE is the difference between an Expiration Date and a Beyond-Use Date (BUD). An expiration date is determined through rigorous commercial stability testing and assigned by the manufacturer for an unopened commercial product or API. A Beyond-Use Date is assigned by the compounding pharmacist to represent the date or time after which a compounded non-sterile preparation (CNSP) must not be used or stored.

In the absence of valid USP-NF monographs or published, stability-indicating analytical studies for a specific formulation, USP <795> mandates standard default conservative BUD limits based on formulation type, storage condition, and water activity ($a_w$):

Standard BUD Limits for Non-Sterile Formulations

1. Non-Aqueous Formulations (Solid dosage forms, capsules, powders, non-aqueous ointments, suppositories, non-aqueous liquids):

   • Maximum BUD: 6 months (180 days) OR the expiration date of any individual component/API, whichever is shorter.
   • Storage Condition: Controlled room temperature (20°C to 25°C [68°F–77°F]).
   • Key Requirement: No water ($a_w < 0.60$) can be present in the vehicle or components.

2. Water-Containing Oral Formulations (Oral solutions, oral suspensions, syrups, oral gels):

   • Maximum BUD: 14 days.
   • Storage Condition: Must be kept under Refrigeration (2°C to 8°C [36°F–46°F]) at all times.
   • Rationale: Water ($a_w \ge 0.60$) combined with oral administration presents a high risk of rapid microbial proliferation and chemical hydrolysis, necessitating cold storage and a tight 14-day limit.

3. Water-Containing Topical, Dermal, and Mucosal Liquid and Semi-Solid Formulations (Creams, gels, lotions, topical sprays, nasal/mucosal sprays, ointments with water):

   • Maximum BUD: 30 days.
   • Storage Condition: Controlled room temperature (20°C to 25°C [68°F–77°F]).
   • Key Distinction: Unlike oral liquids, topical/dermal preparations are applied to skin or mucous membranes and can be stored at room temperature for up to 30 days.

Important Rule for BUD Extension: A compounder may assign an extended BUD beyond default limits ONLY if supported by a validated, stability-indicating analytical method reported in peer-reviewed literature or direct laboratory testing for that specific formulation, container-closure system, and storage temperature.

---

Master Formulation Record vs. Compounding Record

Proper documentation is mandatory under USP <795> and Massachusetts pharmacy law. The Board requires two separate types of recordation:

1. Master Formulation Record (MFR)

• Definition: The official, standardized "recipe" document created before compounding a preparation for the first time.
• Purpose: Ensures consistency, reproducibility, and quality across different batches.
• Mandatory Elements: Name, strength, and dosage form of the preparation; calculation formulas; complete list of active and inactive ingredients with exact quantities; specialized equipment needed; step-by-step mixing and compounding instructions; container/closure system; BUD calculation rationale; storage conditions; quality control procedures (e.g., visual inspection, pH checking); labeling instructions.

2. Compounding Record (CR)

• Definition: The actual operational batch log created during the preparation of a specific individual compounded product.
• Purpose: Provides traceability and evidence of proper execution for every single prescription batch.
• Mandatory Elements: Official name, strength, and dosage form; Master Formulation Record reference; date and time of compounding; unique internal prescription or batch identification number; manufacturer, lot numbers, and expiration dates of every ingredient used; exact measured weight or volume of each ingredient; identity and signature of the compounding technician/pharmacist who weighed and mixed ingredients; identity and signature of the verifying pharmacist; total quantity prepared (yield); assigned BUD and storage instructions; physical quality control observation findings.

---

Massachusetts Requirements — draft 247 CMR 18.00

[!WARNING] 247 CMR 17.00 and 18.00 are Board drafts, not promulgated regulations. Both documents are headed DRAFT (proposed new section), and the promulgated compilation of the Board's rules stops at 247 CMR 21.00; the Board's own pharmacy application checklist still tells applicants to review the draft non-sterile compounding regulations. What binds today is M.G.L. c. 112, §§ 39F through 39J, the compounding licence categories in 247 CMR 6.00, the duty in 247 CMR 9.01(3) to adhere to the most current USP chapters, and published Board policy. Learn the draft numbers because they are how the Board describes its expectations and how question writers refer to them — but if an item asks what a promulgated regulation requires, the answer runs through c. 112, 247 CMR 6.00 and USP.

Massachusetts licenses non-sterile compounding by tier, and the facility standards are stated in square feet.

Licensure mechanics

• An application for a complex non-sterile compounding licence must include certified blueprints of the dedicated compounding room showing the placement of containment hoods, a detailed HVAC design plan with a written description, and an attestation of intent to compound signed by the Manager of Record, the pharmacist in charge of complex non-sterile compounding where applicable, and the applicant.
• The applicant must achieve a satisfactory Board inspection of the proposed pharmacy before an original licence is issued.
• A complex non-sterile compounding licence expires on December 31 of each year following issuance, and the renewal application must include copies of all reports and correspondence relating to inspections by any state or federal agency during the licensing period.

Continuing education

A registrant who oversees or is directly engaged in complex non-sterile compounding, or who practises in a pharmacy licensed under M.G.L. c. 112, § 39H, must complete at least 3 contact hours of continuing education in complex non-sterile compounding each calendar year (247 CMR 4.03(4)(d)).

Reporting — 247 CMR 20.06

A complex non-sterile compounding pharmacy must:

• report to the Board annually, or on request, a list of complex non-sterile prescriptions dispensed within and outside the Commonwealth with their volume, the states in which they were dispensed, and the status of any non-resident licences held; and
• report within seven days of identification any defective complex non-sterile compounded preparation dispensed into or from Massachusetts.

The Manager of Record must also disclose principal managers, certify compliance with the Board's informational requests, certify that continuing education and staff training obligations have been met before staff engage in compounding, submit the names and titles of all employees, and file an updated report annually and within 30 days after any transfer of ownership or change in corporate officers, management personnel or Manager of Record.

503A and 503B

A licensed pharmacy compounding for an identified individual patient pursuant to a prescription operates under section 503A of the FD&C Act. An outsourcing facility compounding in bulk without individual prescriptions registers under section 503B, and Massachusetts registers outsourcing facilities under 247 CMR 21.00. The dividing line is the individual patient prescription, and it is the line the MPJE tests.

---

Worked Traps

• A pharmacy prepares transdermal gels from bulk active pharmaceutical ingredients in an 80-square-foot room. Two failures: the Board's complex non-sterile standard is dedicated rooms totalling at least 100 square feet, and the work requires a complex non-sterile compounding licence under M.G.L. c. 112, § 39H.
• A pharmacy assigns a 90-day beyond-use date to a water-containing oral suspension because the ingredients expire later. Wrong — the default for a water-containing oral formulation is 14 days refrigerated, unless a validated stability-indicating study supports longer for that exact formulation, container and storage condition.
• A defective compounded preparation is identified and reported at the next annual filing. Late — 247 CMR 20.06(3) requires a report within seven days of identification.